Search Within

Anthony R Mato

Formats
  1. Meeting Abstract (135)
  2. Journal Article (63)
  3. Review (16)
  4. Research Letter (10)
  5. Editorial (7)
  6. Guidelines (3)
  7. Book Section (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (236)
  2. Center for Hematologic Malignancies (236)
  3. Department of Medicine (236)
  4. Hematologic Malignancies, Division of (236)
  5. Hematology-Oncology Fellows (101)
  6. Lymphoma (47)

More Groups

People
  1. Lindsey Roeker (94)
  2. Andrew Zelenetz (33)
  3. Meghan Thompson (30)
  4. Omar Abdel-Wahab (19)
  5. Maria Palomba (18)
  6. Colleen Dorsey (14)

More People

Years
  1. 2025 (4)
  2. 2024 (2)
  3. 2023 (22)
  4. 2022 (49)
  5. 2021 (39)
  6. 2020 (52)

More Years

Publications
  1. Blood (82)
  2. Journal of Clinical Oncology (18)
  3. Clinical Lymphoma, Myeloma and Leukemia (16)
  4. Leukemia and Lymphoma (16)
  5. British Journal of Haematology (15)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (94)
  2. American Society of Clinical Oncology (19)
  3. Elsevier Inc. (18)
  4. Taylor & Francis Group (18)
  5. John Wiley & Sons (16)
  6. American Association for Cancer Research (10)

More Publishers

Results (236)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: A real-world database study
    Journal Article

    Eyre, T. A.; Hess, L. M.; Sugihara, T.; He, D.; Khanal, M.; Pagel, J. M.; Walgren, R. A.; Abada, P. B.; Konig, H.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Treatment discontinuation patterns for patients with chronic lymphocytic leukemia in real-world settings: Results from a multi-center international study
    Journal Article

    Shadman, M.; Manzoor, B. S.; Sail, K.; Tuncer, H. H.; Allan, J. N.; Ujjani, C.; Emechebe, N.; Kamalakar, R.; Coombs, C. C.; Leslie, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical experience with drugs targeting Bruton's Tyrosine Kinase (BTK)
    Book Section

    Aronson, J.; Mato, A. R.; Coombs, C. C.; Islam, P.; Roeker, L. E.; Eyre, T.
    In O'Connor, O. A.; Ansell, S. M.; Seymour, J. F. (Eds.) Precision Cancer Therapies (2023)

    Fulltext@MSK | Save
  • Clonal characterization and somatic hypermutation assessment by next-generation sequencing in chronic lymphocytic leukemia/small lymphocytic lymphoma: A detailed description of the technical performance, clinical utility, and platform comparison
    Journal Article

    Petrova-Drus, K.; Syed, M.; Yu, W.; Hutt, K.; Zlotnicki, A. M.; Huang, Y.; Kamalska-Cyganik, M.; Maciag, L.; Wang, M.; Ma, Y. G.; more...
    Journal of Molecular Diagnostics (2023)

    Fulltext@MSK | Save
  • DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study
    Journal Article

    Huntington, S. F.; Schuster, S. J.; Ding, W.; Koehler, A. B.; Brander, D. M.; Rosenthal, A. C.; Leis, J. F.; Tun, H. W.; Moustafa, M. A.; Iqbal, M.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: Identifying risk factors to help guide treatment selection
    Journal Article

    Bantilan, K. S.; Kay, N. E.; Parikh, S. A.; Rabe, K. G.; Call, T. G.; Leis, J. F.; Ding, W.; Slager, S. L.; Soumerai, J. D.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • COVID-19 vaccination response and its practical application in patients with chronic lymphocytic leukemia
    Review

    Shadman, M.; Liu, C.; Eakle, K.; Hiew, H. J.; Biondo, J. M. L.; Ghia, P.; Mato, A. R.
    HemaSphere (2023)

    Fulltext@MSK | Save
  • Outcomes for patients with chronic lymphocytic leukemia (CLL) previously treated with both a covalent BTK and BCL2 inhibitor in the United States: A real-world database study
    Journal Article

    Mato, A. R.; Hess, L. M.; Chen, Y.; Abada, P. B.; Konig, H.; Pagel, J. M.; Walgren, R. A.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Patterns of Treatment and Prognostic Testing Among Black Patients With Chronic Lymphocytic Leukemia (CLL): Results From informCLL, a Prospective, Observational Registry
    Meeting Abstract

    Barrientos, J.; Mato, A.; Sharman, J.; Brander, D.; Gutierrez, M.; Wu, L. D.; Panjabi, S.; Young, A.; Upasani, S.; Naganuma, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save